5 Amino 1MQ.

5 Amino 1MQ is a research compound.

Its biological effect is described in the mechanism section.

It draws interest for various research areas.

F-tier evidence: no meaningful human evidence; support is preclinical or mechanistic.

What it is

5-Amino-1MQ (5-amino-1-methylquinolinium) is a small-molecule, substrate-site inhibitor of the enzyme nicotinamide N-methyltransferase (NNMT). Despite being grouped with "peptides" in the research-chemical marketplace, it is not a peptide at all but a methylquinolinium heterocyclic salt that emerged from academic medicinal-chemistry work at the University of Texas aimed at producing membrane-permeable NNMT inhibitors. It is an investigational research compound, not an approved drug.

How it works

NNMT is a cytosolic enzyme that transfers a methyl group from S-adenosylmethionine (SAM) to nicotinamide, generating 1-methylnicotinamide (1-MNA) and S-adenosylhomocysteine (SAH). Because nicotinamide is the precursor for NAD+ salvage, high NNMT activity in adipose tissue is thought to drain nicotinamide away from NAD+ synthesis and consume SAM. By occupying the nicotinamide substrate site, 5-Amino-1MQ lowers cellular 1-MNA and is proposed to spare nicotinamide for NAD+ regeneration and free up SAM-cycle methylation capacity. The downstream hypothesis—elevated NAD+ activating sirtuins/AMPK to favor energy expenditure over lipid storage—is mechanistically plausible but is largely inferred from cell and rodent work rather than directly demonstrated in humans.

What the evidence shows

The core evidence is preclinical. Neelakantan et al. (Biochemical Pharmacology, 2018) reported that methylquinolinium NNMT inhibitors including 5-Amino-1MQ were membrane-permeable, relatively selective, lowered intracellular 1-MNA, and reduced lipogenesis in 3T3-L1 adipocytes; in diet-induced obese mice on a high-fat diet, systemic NNMT-inhibitor treatment significantly reduced body weight, white adipose mass, and adipocyte size and lowered plasma total cholesterol without changing food intake or producing observable adverse effects. Supporting context comes from Ehebauer et al. (Life Sciences, 2020) on glucose-dependent NNMT regulation in adipocytes, and Dimet-Wiley et al. (Scientific Reports, 2022) combining NNMT inhibition with calorie restriction in obese mice. There are no published human clinical trials, and no human pharmacokinetic or efficacy data for 5-Amino-1MQ have been reported—the human-vs-animal gap here is large and should not be glossed over.

Safety considerations

Documented safety data are limited to short rodent studies, in which investigators reported no overt adverse effects at the doses tested; this is not a substitute for human safety characterization. There are no published human toxicology, drug-interaction, long-term, or reproductive-safety data. Theoretical concerns include the broad and context-dependent roles of NNMT and NAD+/SAM metabolism across tissues (liver, cancer, vasculature), the unknown consequences of chronically altering one-carbon/methylation flux, and the unverified purity and identity of material sold as a "research chemical." Because human safety is essentially uncharacterized, it should be regarded as an experimental compound of unknown human risk.

Regulatory status

5-Amino-1MQ is not approved by the FDA (or any major regulator) for any indication and is not a recognized dietary supplement; it is an investigational/research-use-only compound with no publicly documented IND or registered human clinical trials. It is not, as of this writing, a WADA-listed prohibited substance by name, though its NAD+/metabolic mechanism is the kind of area anti-doping bodies monitor.

1. [1]Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice — Biochemical Pharmacology, 2018, PMID 29155147
2. [2]Noncoupled Fluorescent Assay for Direct Real-Time Monitoring of Nicotinamide N-Methyltransferase Activity — Biochemistry, 2017, PMID 28121423
3. [3]Glucose availability regulates nicotinamide N-methyltransferase expression in adipocytes — Life Sciences, 2020, PMID 32112869
4. [4]Reduced calorie diet combined with NNMT inhibition establishes a distinct microbiome in DIO mice — Scientific Reports, 2022, PMID 35013352

• Not FDA-approved; research-only.
• Human data is minimal; metabolic claims are preclinical.

Stack fit

Why not D: held back by human evidence, preclinical depth, safety clarity, regulatory clarity, practical relevance.

What would move it up: Larger controlled human trials, clearer long-term safety, replicated findings, and regulatory progress.

What would move it down: Failed confirmatory trials, new safety signals, or evidence that popular claims don't translate.

• 5 Amino 1MQ is not FDA-approved for human use; it is discussed in a research context.

• Whether observed effects reliably translate to humans at large.
• Long-term safety in healthy users, and full drug-interaction risk.
• Optimal studied parameters outside any approved indication.
• Claim-by-claim verdicts — these are authored against verified sources and shown when complete.
• Quality and purity of material from non-pharmaceutical sources.

1. What it is
2. The early-evidence lane
3. Why Minimal, and not higher or lower
4. Proven lane vs speculative lane
5. What people report
6. Regulatory status
7. What changed recently